Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103217 | 1.00 | PARP1 (0.46) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| SCHEMBL102293 | 1.00 | PARP1 (0.46) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Potassium SCHEMBL30616188 | 0.98 | PARP1 (0.45) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Methane SCHEMBL28975622 | 0.98 | PARP1 (0.45) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Hydrochloric Acid SCHEMBL377440 | 0.98 | PARP1 (0.45) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Urea SCHEMBL4458708 | 0.95 | PARP1 (0.43) | PARP1USP2SMN1; SMN2HSD17B10DPP4 | |
| SCHEMBL25212939 | 0.90 | PARP1 (0.41) | PARP1USP2SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL25268281 | 0.90 | PARP1 (0.41) | PARP1USP2SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL25416105 | 0.90 | PARP1 (0.41) | PARP1USP2SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL22604987 | 0.88 | HPGD (0.41) | PARP1SMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907387-A | Pyrimidopyrrole KRAS inhibitor and preparation method and application thereof | 中山大学 | 2022-08-16 | — | — | CN | claimed |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| CN-122094678-A | AP 2-related kinase 1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12617784-B2 | AKT inhibitor | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-4731262-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | SUNESIS PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051797-A2 | SMALL-MOLECULE INHIBITORS OF INTERLEUKIN-2 | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2003-04-10 | — | — | US | disclosed |
| US-20030008877-A1 | CCR5 antagonists useful for treating AIDS | SCHERING CORPORATION | 2003-01-09 | — | — | US | disclosed |
| WO-2002079194-A1 | CCR5 ANTAGONISTS USEFUL FOR TREATING AIDS | SCHERING CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| US-6391865-B1 | AIDS THERAPY; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; SKIN DISORDERS | SCHERING CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-0836383-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-22 | — | — | EP | disclosed |
| US-5736539-A | ANITCARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| WO-1995000497-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | PARP1 3042/4885USP2 3299/4885SMN1; SMN2 3529/4885 |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PARP1 588/4885USP2 4498/4885SMN1; SMN2 2272/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | PARP1 3084/4885USP2 2189/4885SMN1; SMN2 2865/4885 |
| US-12617784-B2 | AKT inhibitor | AKT2, AKT1, AKT3 | PARP1 1111/4885USP2 3420/4885SMN1; SMN2 1551/4885 |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | PARP1 1865/4885USP2 4689/4885SMN1; SMN2 3412/4885 |
| US-20030008877-A1 | CCR5 antagonists useful for treating AIDS | CCR5, CCR1, CXCR3 | PARP1 1954/4885USP2 4503/4885SMN1; SMN2 3000/4885 |
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | IL2, IL2RA, HLA-DRB1 | PARP1 4460/4885USP2 1421/4885SMN1; SMN2 3620/4885 |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | OGFR, CBR3, CBR1 | PARP1 2439/4885USP2 4064/4885SMN1; SMN2 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.